Roszkowska A M, Biondi S, Chisari G, Messina A, Ferreri F M B, Meduri A
Ophthalmology Clinic, Department of Surgical Specialities, Univ. of Messina, Messina, Italy.
Eur J Ophthalmol. 2006 Mar-Apr;16(2):214-8. doi: 10.1177/112067210601600204.
To evaluate the visual and refractive outcome in adult patients wi th refractive and anisometropic amblyopia treated with photorefractive keratectomy.
An interventional non-comparative study was performed on 50 consecutive patients with amblyopia treated with photorefractive keratectomy. Sixty-eight eyes of 18 participants with bilateral refractive amblyopia and 32 participants with unilateral anisometropic amblyopia were studied. The photorefractive keratectomy was performed with MEL 70 G-Scan excimer laser. Follow-up was 1, 3, 6, and 12 months after the treatment. The mean outcome measures were uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BCVA), refraction, and corneal transparency.
In 64.7% of eyes, the UCVA at 12 months after the treatment was better than or equal to their preoperative BCVA. A total of 82.4% of eyes improved their BCVA one or more lines. No eye lost lines of BCVA, 17.6% remained unvaried, 50% gained one line, 20.6 % gained two lines, and 11.8% gained three lines of BCVA. The number of lines gained correlated strongly with diopters of anisometropia between eyes (p<0.01). The mean sphere changed from -5.62+/-3.37 D to -0.47+/-1 D, mean cylinder varied from -2.36+/-1.57 to -0.18+/-0.41 D, and the spherical equivalent varied from -6.82+/-3.1 to -0.45+/-1.08 D. No clinically significant haze was observed.
Excimer laser refractive surgery appears to be a safe and efficient procedure in the treatment of ametropic and anisometropic amblyopia in adults. Adult patients with anisometropic and refractive amblyopia could benefit from the refractive treatment with significant improvement of the visual acuity.
评估接受准分子激光原位角膜磨镶术（PRK）治疗的屈光不正性和屈光参差性弱视成年患者的视力和屈光结果。
对50例连续接受PRK治疗的弱视患者进行了一项非对照干预性研究。研究了18例双侧屈光不正性弱视患者和32例单侧屈光参差性弱视患者的68只眼。使用MEL 70 G-Scan准分子激光进行PRK。治疗后随访1、3、6和12个月。主要观察指标为裸眼视力（UCVA）、最佳矫正视力（BCVA）、屈光状态和角膜透明度。
64.7%的患眼在治疗后12个月时UCVA优于或等于术前BCVA。共有82.4%的患眼BCVA提高了一行或多行。没有患眼BCVA下降，17.6%保持不变，50%提高了一行，20.6%提高了两行，11.8%提高了三行。BCVA提高的行数与双眼屈光参差度数密切相关（p<0.01）。平均球镜度数从-5.62±3.37 D变为-0.47±1 D，平均柱镜度数从-2.36±1.57变为-0.18±0.41 D，等效球镜度数从-6.82±3.1变为-0.45±1.08 D。未观察到具有临床意义的角膜 haze。
准分子激光屈光手术似乎是治疗成人屈光不正性和屈光参差性弱视的一种安全有效的方法。患有屈光参差性和屈光不正性弱视的成年患者可从屈光治疗中获益，视力有显著改善。
